Sandeep Jauhar’s grandfather was sitting down to lunch with family when he crumpled to the floor. Jeff Kwitowski’s father was on a routine bike ride. Cat Davis Ahmed’s father was enjoying a game of tennis. And Florence Champagne was in an office building when she dropped to her knees, gasping for air and praying for her life.
Heart attack and stroke don’t just affect patients across Europe, new research reveals.
On April 9, a congressional hearing will explore the impact of pharmacy benefit managers on high drug prices. It’s a connection that many heart patients have learned firsthand.
More than 50 percent of Europeans have raised cholesterol, increasing their risk of heart attack, stroke and death – and costing the EU billions every year in health care expenses and lost productivity. So explains a new “Fast Facts” policy brief from the European Alliance for Patient Access, a division of the Global Alliance for Patient Access.
England has a plan. It’s comprehensive, long term and aimed at preventing 150,000 heart attacks and strokes over the next 10 years. How? By, among other measures, reducing high cholesterol, hypertension and atrial fibrillation.
Patient advocates across the country cheered this week as news spread about a decrease in the list price of evolocumab.
A massive stroke marked a serious change in the weather for Mark McEwen, whose familiar face brought viewers the weather forecast on the 1990s’ “CBS This Morning.” McEwen keynoted the May 15 Cardiovascular Health Policy Summit in Washington, DC, describing how he struggled to regain speech, mobility and fine motor skills.
Heart patients in Europe have something to celebrate.
Blue Cross Blue Shield of Mississippi, the largest private insurer in the state, approved just 3 percent of claims in 2017 for a newer medication that treats high cholesterol in specific patients, according to a report from the Institute for Patient Access.
